IRMD
Iradimed Corp Health Care Surgical & Medical Instruments & Apparatus Russell 3000
$76.68Close
$980.1MMarket cap
$75.38 – $104.6352-week range
Late-januaryNext report · estimated
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 22 · weaker than 78% of stocks over 12 months
- Far from its high 27% below its 52-week high
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
27%
1wk
down 10.7%
price change
1mo
down 11.1%
price change
12-month return
up 2%
market up 11% ·
its own down 12%
F-score
6 / 9
Mixed
Altman Z
44.71
Low risk
P/E
43.6×
price / earnings
PEG
2.68
P/E / EPS growth
P/B
10.4×
price / book
Earnings yield
up 2.8%
EBIT / enterprise value
Cheaper than
31%
of the market · expensive
Revenue growth
up 14%
year on year
EPS growth
up 17%
latest quarter · +26 pts
Sales growth
up 14%
latest quarter · +14 pts
ROE
up 25%
return on equity
Free cash margin
up 21%
$17.2M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-1.9×
net cash
Interest cover
—EBIT / interest
Piotroski tests
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- profitable on its assets
- generating cash from operations
- profitability improving
- profits backed by cash
- reduced long-term debt
- assets working harder
Trade setup
ATR%
3.4%
$2.60 a day · 2×ATR $71.49
RS
22 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
1.9×
vs 50-day average
Up/down volume
0.78
50 sessions
Implied move
—
no scheduled report
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Oct 30, 2026
Results reaction
Oct 30, 2026-9% vs market2 sessions after results
Financials
- Gross 77%
- Net 27%
- Free cash 21%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $31.7M | $41.8M | $53.3M | $65.6M | $73.2M | $83.8M |
| Gross margin | 74% | 77% | 77% | 77% | 77% | 77% |
| Operating income | -$756,091 | $9.8M | $15.6M | $20.0M | $22.0M | $26.1M |
| Net income | $1.4M | $9.3M | $12.8M | $17.2M | $19.2M | $22.5M |
| Net margin | 4% | 22% | 24% | 26% | 26% | 27% |
| Earnings per share | $0.11 | $0.74 | $1.02 | $1.35 | $1.50 | $1.75 |
| Free cash flow | $5.4M | $10.8M | $9.2M | $6.0M | $17.6M | $17.2M |
| Free cash margin | 17% | 26% | 17% | 9% | 24% | 21% |
| Cash | $50.1M | $62.0M | $58.0M | $49.8M | $52.2M | $51.2M |
| Shareholders' equity | $61.4M | $72.2M | $73.7M | $71.4M | $86.8M | $94.6M |
| Shares outstanding | 12.31m | 12.54m | 12.59m | 12.66m | 12.71m | 12.78m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 30, 2026 | Quarterly ↗ | Sep 30, 2026 | 30d |
| Jul 31, 2026 | Quarterly ↗ | Jun 30, 2026 | 31d |
| May 1, 2026 | Quarterly ↗ | Mar 31, 2026 | 31d |
| Mar 6, 2026 | Annual ↗ | Dec 31, 2025 | 65d |
| Nov 3, 2025 | Quarterly ↗ | Sep 30, 2025 | 34d |
| Aug 1, 2025 | Quarterly ↗ | Jun 30, 2025 | 32d |
| May 5, 2025 | Quarterly ↗ | Mar 31, 2025 | 35d |
| Mar 6, 2025 | Annual ↗ | Dec 31, 2024 | 65d |
| Oct 31, 2024 | Quarterly ↗ | Sep 30, 2024 | 31d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Mar 1, 2024 | Annual ↗ | Dec 31, 2023 | 61d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 30, 2026 | Results ↗ |
| Jul 31, 2026 | Other events ↗ |
| Jun 24, 2026 | Shareholder vote ↗ |
| May 1, 2026 | Results ↗ |
| Feb 10, 2026 | Results ↗ |
| Dec 8, 2025 | Other events ↗ |
| Nov 3, 2025 | Results ↗ |
| Sep 2, 2025 | Director or officer change · Regulation FD ↗ |
| Aug 1, 2025 | Results ↗ |
| Jun 23, 2025 | Shareholder vote ↗ |
| May 29, 2025 | Other events ↗ |
| May 5, 2025 | Results ↗ |